spacer
home > ebr > summer 2002 > singapore - a world class hub for biomedical sciences
PUBLICATIONS
European Biopharmaceutical Review

Singapore - A World Class Hub for Biomedical Sciences

Home to over 6,000 international companies with a strong base of electronics, engineering and chemical players, Singapore has also been selling itself as 'The Biopolis of Asia'. It is fast becoming a preferred location for many global biomedical companies. For a young nation with no natural resources, cosmopolitan Singapore is definitely putting itself firmly on the BioScience map. Today, Singapore has a strong contingent of leading international companies in pharmaceuticals, biotechnology, medical technology and health care services. With quality manpower, a good infrastructure, global market networks and strong intellectual property rights protection, Singapore offers an excellent operating environment for biomedical sciences companies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Tan Hsueh Mei, Marketing Communications Department at the Singapore Economic Development Board
Tan Hsueh Mei works with the Marketing Communications Department at the Singapore Economic Development Board, promoting Singapore as an investment location.
Specifically, she oversees the marketing and communications needs of the Biomedical Sciences Group in EDB. She holds an Honours Degree in Sociology/Anthropology from the National University of Singapore.

spacer
Tan Hsueh Mei
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

High Potency Drugs – from Molecule to Market

PCI Pharma Services

PCI Pharma Services has invested in state-of-the-art containment equipment and created a ‘Potent Passport’ philosophy to identify the specific handling requirements for any Highly Potent Active Pharmaceutical Ingredients (HPAPI) project. Backed by 30 years’ experience of managing potent molecules, PCI Pharma Services is the logical choice when selecting an outsourcing partner.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement